Mariotti S, Caturegli P, Barbesino G, Del Prete G F, Chiovato L, Pinchera A
Istituto di Endocrinologia, University of Pisa, Italy.
J Endocrinol Invest. 1991 Oct;14(9):777-81. doi: 10.1007/BF03347915.
High serum concentration of soluble interleukin-2 receptor (sIL-2R) is considered a reliable marker of T lymphocyte activation. It has been recently reported that sIL-2R levels are increased in untreated Graves' disease. This finding has been interpreted as the consequence of an active autoimmune state, but the relevance of the thyroid function per se was not investigated. In the present study we assayed sIL-2R by ELISA in 20 normal subjects and in a series of patients with immunogenic (Graves' disease, GD) or nonimmunogenic (toxic adenoma, TA) hyperthyroidism. Significant increased concentrations of sIL-2R were found in 46 patients with untreated hyperthyroid GD (mean +/- SD: 1,683 +/- 1016 U/ml, vs 461 +/- 186 U/ml in normal controls, p less than 0.0001) and in 21 with untreated TA (1,111 +/- 617 U/ml, p less than 0.0001 vs normals). Restoration of the euthyroid state by antithyroid drugs or 131I administration was associated with a normalization of sIL-2R (516 +/- 174 U/ml in 38 patients with GD and 365 +/- 90 U/ml in 12 with TA; p = NS vs normals and p less than 0.001 vs the untreated state for both groups). A highly significant positive correlation between serum sIL-2R and free triiodothyronine (FT3) (r = 0.724, p less than 0.0001) or free thyroxine (FT4) (r = 0.698, p less than 0.0001) concentrations was found in combined sera obtained from all untreated and treated patients, irrespectively of the autoimmune or nonautoimmune nature of the underlying hyperthyroid disease.(ABSTRACT TRUNCATED AT 250 WORDS)
血清中可溶性白细胞介素-2受体(sIL-2R)浓度升高被认为是T淋巴细胞活化的可靠标志物。最近有报道称,未经治疗的格雷夫斯病患者的sIL-2R水平会升高。这一发现被解释为活跃自身免疫状态的结果,但甲状腺功能本身的相关性并未得到研究。在本研究中,我们采用酶联免疫吸附测定法(ELISA)对20名正常受试者以及一系列免疫原性(格雷夫斯病,GD)或非免疫原性(毒性腺瘤,TA)甲状腺功能亢进患者的sIL-2R进行了检测。在46例未经治疗的甲状腺功能亢进GD患者中发现sIL-2R浓度显著升高(均值±标准差:1683±1016 U/ml,而正常对照组为461±186 U/ml,p<0.0001),21例未经治疗的TA患者中也是如此(1111±617 U/ml,与正常组相比p<0.0001)。通过抗甲状腺药物或服用131I使甲状腺功能恢复正常状态与sIL-2R的正常化相关(38例GD患者为516±174 U/ml,12例TA患者为365±90 U/ml;与正常组相比p无统计学意义,两组与未经治疗状态相比p<0.001)。在所有未经治疗和已治疗患者的混合血清中,发现血清sIL-2R与游离三碘甲状腺原氨酸(FT3)(r = 0.724,p<0.0001)或游离甲状腺素(FT4)(r = 0.698,p<0.0001)浓度之间存在高度显著的正相关,无论基础甲状腺功能亢进疾病的自身免疫性或非自身免疫性如何。(摘要截选至250词)